{
  "url": "https://struct.news/briefs/gileads-us-sales-run-through-three-wholesalers",
  "title": "Gilead’s U.S. sales run through three wholesalers",
  "summary": "Gilead’s disclosed relationship map is less about a sprawling supplier base than a narrow route to market: three wholesalers have historically handled roughly 90% of its U.S. product sales, while the company builds a separate web of biotech partnerships.",
  "published_at": "2026-08-04T09:18:13.858842+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "Gilead Sciences, Inc.",
    "ticker": "GILD",
    "cik": null,
    "sector": "Healthcare",
    "industry": null
  },
  "source_filing": null,
  "comparison_filing": null,
  "reported_figures": [
    {
      "group": "Gilead’s disclosed relationship map",
      "label": "CAH",
      "value": "CAH",
      "display": "CAH",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-04"
      }
    },
    {
      "group": "Gilead’s disclosed relationship map",
      "label": "COR",
      "value": "COR",
      "display": "COR",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-04"
      }
    },
    {
      "group": "Gilead’s disclosed relationship map",
      "label": "CAH",
      "value": "CAH",
      "display": "CAH",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-04"
      }
    },
    {
      "group": "Gilead’s disclosed relationship map",
      "label": "KYMR",
      "value": "KYMR",
      "display": "KYMR",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-04"
      }
    },
    {
      "group": "Gilead’s disclosed relationship map",
      "label": "RS",
      "value": "RS",
      "display": "RS",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-04"
      }
    },
    {
      "group": "Gilead’s disclosed relationship map",
      "label": "RCUS",
      "value": "RCUS",
      "display": "RCUS",
      "unit": "ticker",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Named in SEC filings",
        "as_of": "2026-08-04"
      }
    }
  ],
  "watch_next": [
    {
      "type": "demand",
      "statement": "For Q2 2026, tons sold rose 10.8% and average selling price per ton rose 14.5% year-over-year, reflecting strong underlying demand across most end markets.",
      "importance": "medium",
      "evidence": "For the second quarter of 2026, tons sold increased 10.8% and average selling price per ton sold improved 14.5% year-over-year, reflecting strong underlying demand across most end markets.",
      "source_date": "2026-07-28"
    },
    {
      "type": "product_pipeline",
      "statement": "Quarterly R&D expense was $208,323 (thousands) for the three months ended Apr 30, 2026, a $24,290 increase vs prior year driven primarily by $18M higher employee compensation and headcount.",
      "importance": "medium",
      "evidence": "Research and development $ 208,323 $ 184,033 $ 24,290 13% Percentage of total revenues 24 % 24 % Research and development expenses for the three months ended April 30, 2026 increased $24 million, primarily due to an increase of $18 million in employee compensation-related costs, which was driven by increases in salaries and benefits, as well as an increase in headcount.",
      "source_date": "2026-06-05"
    },
    {
      "type": "liquidity_financing",
      "statement": "On April 24, 2026 McKesson replaced prior facilities with a $5.0 billion syndicated senior unsecured credit facility with a $4.5 billion aggregate sublimit in CAD, GBP, and EUR.",
      "importance": "medium",
      "evidence": "On April 24, 2026, we terminated our 2022 revolving credit facility and our 364-Day credit facility and entered into a new Credit Agreement (the “2026 Credit Facility”) that provides a syndicated $5.0 billion senior unsecured credit facility with a $4.5 billion aggregate sublimit of availability in Canadian dollars, British pound sterling, and Euro.",
      "source_date": "2026-05-08"
    },
    {
      "type": "demand",
      "statement": "Oncology Cell Therapy product sales decreased 12% to $407 million for the three months ended March 31, 2026, primarily due to lower demand reflecting ongoing competitive headwinds.",
      "importance": "medium",
      "evidence": "Oncology Cell Therapy Cell Therapy product sales decreased 12% to $407 million for the three months ended March 31, 2026, compared to the same period in 2025, primarily due to lower demand reflecting ongoing competitive headwinds.",
      "source_date": "2026-05-07"
    }
  ],
  "related_tickers": [
    "ASMB",
    "CAH",
    "COR",
    "GILD",
    "KYMR",
    "LGND",
    "MCK",
    "NRIX",
    "RCUS",
    "RS",
    "VEEV"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}